GSK unveils plan for one of Europe’s largest life science campuses in Stevenage
Published on 16 Jul 2021
Autolus Announces Appointment of Edgar Braendle, M.D., Ph.D., as Chief Development Officer
Published on 15 Jul 2021
HLEP - SMEs are core foundation of Hertfordshire’s strategy to build back from COVID-19
Published on 15 Jul 2021
Galecto Resumes Recruitment in Phase 2b Global GALACTIC-1 Trial of GB0139 for Idiopathic Pulmonary Fibrosis
Published on 13 Jul 2021
NeRRe Therapeutics raises £20 million in a Series B2 financing round
Published on 7 Jul 2021
Revolo Biotherapeutics Announces the Appointments of Marla S. Persky and Glen Giovannetti to its Board of Directors
Published on 1 Jul 2021
Revolo Biotherapeutics Announces US FDA Approval of IND Application for Phase 2 Trial of ‘1104 in Eosinophilic Esophagitis
Published on 23 Jun 2021
Gyroscope Therapeutics Announces Research Collaboration Agreement with Children’s Medical Research Institute to Develop Novel Gene Therapy Capsids
Published on 22 Jun 2021
Apollo Therapeutics Completes $145 Million Financing Led by Patient Square Capital to Expand and Advance Portfolio-Based Drug Development
Published on 17 Jun 2021

Peptinnovate announces change of name to Immune Regulation, strengthening of the Board and successful fundraise

Read the article
The appointment of these three experienced industry executives will bring valuable insight and resource to our Board and executive team. With their skills in immunology, clinical therapeutic development and strategy we have the expertise to advance our clinical programmes and look forward to the next stage of our progress.
Prof. Clive Page
Chairman of Immune Regulation
ReViral Announces Positive Recommendation by the Data Safety Monitoring Committee to Continue the Phase 2 Clinical Study of Sisunatovir for Treatment of Respiratory Syncytial Virus Infections in Hospitalized Infants
Published on 16 Jun 2021
Freeline Doses Second Patient of Phase 1/2 MARVEL-1 Clinical Trial for Fabry Disease
Published on 16 Jun 2021
Autolus Therapeutics Announces Innovation Licensing and Access Pathway (ILAP) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL
Published on 15 Jun 2021
Ossianix Announces Publication of Positive Preclinical Data on Neutralizing SARS-CoV-2 Infection with a Panel of Single Domain Shark VNAR Antibodies
Published on 10 Jun 2021
Revolo Biotherapeutics Enters into Partnership Agreement with Northway Biotech to Manufacture its Novel Binding Immunoglobulin Protein, ‘1805, to Support Phase 2 Trials in Rheumatoid Arthritis and Uveitis
Published on 9 Jun 2021
Cell and Gene Therapy Catapult brings together over 20 organisations with the aim to accelerate technology development and potentially lower cost in cell and gene therapy manufacturing
Published on 8 Jun 2021
Exploristics signs collaboration agreement with Istesso to embed study simulation into clinical development with innovative software platform KerusCloud
Published on 4 Jun 2021
New data presented at Virtual EULAR 2021 Congress by AKL Research and Development demonstrate its investigational osteoarthritis drug APPA reduces senescence and reactive oxygen species production
Published on 2 Jun 2021
Cytiva acquires GoSilico to strengthen digital capabilities in bioprocessing
Published on 2 Jun 2021
Plasticell announces completion of £1.4 million equity financing round
Published on 28 May 2021
FourPlus and Cell and Gene Therapy Catapult deliver cutting-edge VR training technology
Published on 27 May 2021
PostEra and LifeArc collaborate on novel open science initiative to develop new antiviral for COVID-19
Published on 20 May 2021

Copyright © 2021 Stevenage Bioscience Catalyst

Designed and built by Onespacemedia

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.